Intra Cellular Therapies Inc (ITCI) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same...

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and...